| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2407 |
| Trial ID | NCT04484012 |
| Disease | Mantle Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Acalabrutinib |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 19405|NCI-2020-04550|19405|P30CA033572 |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||